联系方式

简介

    梁宏，博士，教授。现任十大正规买足球网站省部共建药用资源化学与药物分子工程国家重点实验室/教育部重点实验室主任，博士生导师；曾任十大正规买足球网站校长（2002-2017），广西壮族自治区科协副主席，兼任南开大学、南京大学无机化学博士生导师和中南大学应用化学博士生导师（2001-2013）。在PNAS，Nat. Commun., J. Am.Chem. Soc., Angew. Chem. Int. Ed., Adv. Sci.，ACS Nano，J. Med. Chem.,Small, Eur. J. Med. Chem., Anal. Chem., Inorg.Chem.和CCS Chem.,《中国科学》等国内外期刊发表SCI论文500余篇，并被SCI引用13100余次，H指数58；获授权中国发明专利80余项，欧洲发明专利1项；获得广西科学技术奖特别贡献奖、广西科技进步一等奖和广西自然科学一等奖等省级科技成果奖13项，广西优秀教学成果奖6项。

主要研究方向

1．中药活性成分金属药物化学生物学

2．新型抗肿瘤金属药物和蛋白质载药体系

3．诊疗一体化纳米医药材料

4．生命过程实时原位监测新方法

主要学术兼职

英国皇家化学会会士（FRSC）

中国化学会会士（FCCS）

中国化学会理事

中国化学会无机化学学科委员会委员

中国化学会化学生物学学科委员会委员

广西化学化工学会理事长（2001-2019）、荣誉理事长

国际期刊《Journal of Inorgnic Biochemistry》编委（2019-2012）

国际期刊《Journal of Natural Medicines Research》编委

中国化学会期刊《无机化学学报》编委

中国化学会期刊《化学教育》编委

讲授课程

生物无机化学

主要代表性论文： 

1.      Ke-Bin Huang+, Feng-Yang Wang+, Yuan Lu+, Liang-Mei Yang, Nian Long,Shan-Shan Wang, Zhiying Xie, Matthew Levinec, Taotao Zou*, Jonathan L. Sessler*,Hong Liang*. Cu(II) complex thatsynergistically potentiates cytotoxicity and an antitumor immune response bytargeting cellular redox homeostasis. PNAS, 2024, 121(24), e2404668121.

2.      Peijing Xu+, Changchun Wen+, Cunji Gao*, Huihui Liu, Yingshu Li, Xiaolu Guo,Xing-Can Shen*, Hong Liang*. Near-Infrared-II-ActivatableSelf-Assembled Manganese Porphyrin-Gold Heterostructures for PhotoacousticImaging-Guided Sonodynamic-Augmented Photothermal/Photodynamic Therapy. ACSNano, 2024, 18, 713−727.

3.      Yulong Bai+, JingHua+, Jingjin Zhao*, Shulong Wang, Mengjiao Huang, Yang Wang, YanniLuo, Shulin Zhao*, Hong Liang*. ASilver-Induced Absorption Red-Shifted Dual-Targeted Nanodiagnosis-TreatmentAgent for NIR-II Photoacoustic Imaging-Guided Photothermal and ROSSimultaneously Enhanced Immune Checkpoint Blockade Antitumor Therapy. AdvanceScience, 2023, 2306375.

4.      Qi-Yuan Yang+, Rui Ma+, Yun-Qiong Gu+, Xiao-Fang Xu, Zhen-Feng Chen*, Hong Liang*. Arene-Ruthenium(II)/Osmium(II) ComplexesPotentiate the Anticancer Efficacy of Metformin via Glucose MetabolismReprogramming. Angew. Chem. Int. Ed., 2022, e202208570.

6.      Yan-Lei Ma*, Ji-PingYue*, Yao Zhang*, Chen-Zhang Shi*, Matt Odenwald, Wenguang G. Liang, Qing Wei,Ajay Goel, Xue-Wen Gou, Jamie Zhang, Shao-Yu Chen, Wei-Jen Tang, Jerrold R.Turner, Feng Yang, Hong Liang*,Huan-Long Qin, Xiao-Yang Wu. ACF7 regulates inflammatory colitis and intestinalwound response by orchestrating tight junction dynamics. Nat. Commun. 2017, 8, 15375.

7.      Ji-Ping Yue, YaoZhang, Wen-Guang G. Liang, Xue-Wen Gou, Philbert Lee, Han Liu, Wan-Qing Lyu,Wei-Jen Tang, Shao-Yu Chen, Feng Yang*, HongLiang*, Xiao-Yang Wu*. In Vivo Epidermal Migration Requires FocalAdhesion Targeting of ACF7. Nat.Commun. 2016, 7, 11692.

8.       Yi Gou, GuoJin Huang , Jinlong Li, Feng Yang*, Hong Liang*. Versatiledelivery systems for non-platinum metal-based anticancer therapeutic agents, Coordin. Chem. Rev., 2021, 441, 213975.

9.      Wenjuan Li, Shanhe Li,Zhenlei Zhang, Gang Xu, Xueyu Man, Feng Yang*, Hong Liang*. Developing aMultitargeted Anticancer Palladium(II) Agent Based on the His-242 Residue inthe IIA Subdomain of Human Serum Albumin. J.Med. Chem.,2023, 66, 8564–8579.

10.   Xing Lu, Mei-Feng Wu, Jiang-LunWu, Hai-Qun Zhang, Hong Liang*, Zhen-Feng Chen*. Platinum-Based Mcl‑1 Inhibitor TargetingMitochondria Achieves Enhanced Antitumor Activity as a Single Agent or inCombination  with ABT-199.J. Med. Chem., 2023, 66, 8705−8716.

11.   Zhenlei Zhang†, Juzheng Zhang†,Tongfu Yang†, Shanhe Li, Gang Xu, Hong Liang*, Feng Yang*. Developing an Anticancer Platinum(II) Compound Basedon the Uniqueness of Human Serum Albumin. J.Med. Chem., 2023, 66， 5669−5684.

12.   Xueyu Man§, Tongfu Yang§,Wenjuan Li, Shanhe Li, Gang Xu, Zhenlei Zhang, Hong Liang*, Feng Yang*. Developing a Gadolinium(III) Compound Based onApoferritin for Targeted Magnetic Resonance Imaging and Dual-Modal Therapy ofCancer. J. Med. Chem., 2023, 66, 7268−7279.

13.   Tongfu Yang, Zhenlei Zhang,Juzheng Zhang, Yanping Li, Wenjuan Li, Hong Liang*, Feng Yang*. Developing a Gallium(III) Agent Based on theProperties of the Tumor Microenvironment and Lactoferrin: Achieving Two-AgentCo-delivery and Multi-targeted Combination Therapy of Cancer. J. Med. Chem., 2023, 66， 793−803.

14.    Shuang Kan, Rong Li, Yanhui Tan, Fang Yang, Shaohua Xu, Lingzhu Wang, Lijun Zhang, Xuchen Sun, Xuanming Chen,Yuting Yang, Wei Shu, Huaibin Wan, Zheng-Feng Chen, Hong Liang*, Ming Chen*. Latexin deficiency attenuates adipocyte differentiationand protects mice against obesity and metabolic disorders induced by high-fatdiet. Cell Death & Disease,2022,13(2): 175 .

15.    Wen-Ying Shen, Chun-Peng Jia, Li-Yi Liao,Liu-Lin Chen, Cheng Hou, Yang-HanLiu, Hong Liang*, Zhen-Feng Chen*. Copper(II) Complexes of HalogenatedQuinoline Schiff Base Derivatives Enabled Cancer Therapy throughGlutathione-Assisted Chemodynamic Therapy and Inhibition of Autophagy Flux.  J.Med. Chem., 2022, 65, 5134-5148.

16.   Ming Jiang, YongChu, Tongfu Yang, Wenjuan Li, Zhenlei Zhang, Hongbin Sun, Hong Liang*, Feng Yang*. Developing a Novel Indium(III) AgentBased on Liposomes to Overcome Cisplatin-Induced Resistance in Breast Cancer byMultitargeting the Tumor Microenvironment Components. J. Med. Chem.,2021, 64, 14587–14602.

17.    Shulong Wang, Jingjin Zhao, Liangliang Zhang*, Chaobang Zhang,Zhidong Qiu, Shulin Zhao*. Yong Huang, Hong Liang*. A Unique Multifunctional Nanoenzyme Tailoredfor Triggering Tumor Microenvironment Activated NIR-II Photoacoustic Imagingand Chemodynamic/Photothermal Combined Therapy. Adv. Healthcare Mater., 2021,2102073.

18.    Juzheng Zhang, Ming Jiang, Shanhe Li, Zhenlei Zhang, Hongbin Sun, FengYang*, Hong Liang*. Developing a Novel Anticancer Gold(III) Agent toIntegrate Chemotherapy and Immunotherapy. J.Med. Chem., 2021,64, 6777–6791.

19.    Ju-Zheng Zhang, Zhen-Lei Zhang, Ming Jiang, Shan-He Li, Hao-LiangYuan, Hong-Bin Sun, Feng Yang*, HongLiang*. Developing a novel gold(III) agent to treat glioma based on theunique properties of apoferritin nanoparticles: inducing lethal autophagy andapoptosis，J. Med. Chem., 2020, 63, 13695–13708.

20.   Noor Shad Gul†,Taj-Malook Khan1†, Yan-Cheng Liu, Muhammad Iqbal Choudhary,Zhen-Feng Chen*, Hong Liang*. Pd(II) and Rh(III) Complexes with Isoquinoline DerivativesInduced Mitochondria-Mediated Apoptotic and Autophagic Cell Death in HepG2Cells, CCS Chem., 2020, 2, 1626–1641.

21.    Xing Lu, Yan-Cheng Liu, Chris Orvig, Hong Liang*, Zhen-Feng Chen*. Discovery of aCopper-Based Mcl‑1 Inhibitor as an Effffective Antitumor Agent, J. Med. Chem., 2020, 63, 9154–9167.

22.   Jiayao Xu, Lina Fang, Ming Shi,Yong Huang*, Lifang Yao, Shulin Zhao*, Liangliang Zhang, Hong Liang*. Apeptide-based four-color fluorescent polydopamine nanoprobe for multiplexedsensing and imaging of proteases in living cells. Chem. Commun., 2019, 55,1651–1654.

23.   Zhen-Lei Zhang, Ping Yu, YiGou, Ju-Zheng Zhang, Shan-He Li, Mei-Ling Cai, Hong-Bin Sun, Feng Yang*, HongLiang*. A novel brain-tumor-inhibiting copper(II) compound based on HSA–cell penetrating peptide conjugate. J. Med. Chem., 2019, 62, 10630–13069.

24.    Ke-Bin Huang, Feng-Yang Wang, Hai-Wen Feng, He-Jiang Luo, YanLong, Tao-Tao Zou*, Albert S.C.Chan, Rong Liu, Hua-Hong Zou, Zhen-Feng Chen*,Yan-Cheng Liu, You-Nian Liu, Hong Liang*.An aminophosphonate ester ligand-containing platinum(ii)complex induces potent immunogenic cell death in vitro and elicits effectiveanti-tumour immune responses in vivo. Chem.Commun., 2019, 55, 13066.

25.    Ke-Bin Huang, Feng-Yang Wang, Xiao-Ming Tang, Hai-Wen Feng,Zhen-Feng Chen*, Yan-Cheng Liu, You-Nian Liu,Hong Liang*. Organometallic Gold(III)Complexes Similar to Tetrahydroisoquinoline Induce ER-Stress-Mediated Apoptosisand Pro-Death Autophagy in A549 Cancer Cells. J.Med. Chem., 2018, 61, 3478-3490.

26.    Bang-Ping Jiang, Li Zhang, Xiao-Lu Guo, Xing-Can Shen*, Yan Wang,Yang Zhu, Hong Liang*. Poly(N-phenylglycine)-BasedNanoparticles as Highly Effective and Targeted Near-Infrared PhotothermalTherapy/Photodynamic Therapeutic Agents for Malignant Melanoma. Small, 2017, 13, 1602496.

27.    Zhen-Feng Chen*, Qi-Pin Qin, Jiao-Lan Qin, Jie Zhou, Yu-Lan Li, NanLi, Yan-Cheng Liu, Hong Liang*. Water-solubleruthenium(II) complexes with chiral 4-(2,3-Dihydroxypropyl)-formamideoxoaporphine (FOA): in vitro and in vivo anticancer activity by stabilizationof G-Quadruplex DNA, inhibition of telomerase activity, and induction of tumorcell apoptosis. J. Med. Chem. 2015, 58, 4771–4789.

28.    Zhen-Feng Chen*, Qi-Pin Qin, Jiao-Lan Qin, Yan-Cheng Liu, Ke-BinHuang, Yu-Lan Li, Ting Meng, Guo-Hai Zhang, Yan Peng, Xu-Jian Luo, Hong Liang*.  Stabilization of G-quadruplex DNA, inhibitionof telomerase activity, and tumor cell apoptosis by organoplatinum(II)complexes with oxoisoaporphine. J.Med. Chem.,2015, 58, 2159–2179.

29.    Ming-HuaZeng*,Min-XiaYao, Hong Liang*, Wei-XiongZhang, Xiao-MingChen. A Single-Molecule-Magnetic,Cubane-Based, Triangular Co12 Supercluster. Angew. Chem.Int. Ed., 2007, 46, 1832–1835.

30.    Yi Gou*, Li Liu, Hong Liang*. Editorial on the Research Topic: The Developments of Metal-Based Agents Against Lung Cancer. Front Pharmacol., 2022, 13, 1101890.

近10年以来承担的主要科研项目

（1）973计划专项课题：基于中药活性成分金属抗肿瘤配合物研究和天然环肽类潜药的化学组装与活性评价（255万元）（2012-2015）

（2）国家自然科学基金-重点项目(21431001): 基于中药活性成分金属抗肿瘤配合物研究（360万元）(2015-2019)

（3）国家自然科学基金项目(22177022)：协同调控氧化(异)阿朴菲生物碱金属化合物的细胞毒活性与免疫激活响应研究 （60万元）(2022-2025)

（4）国家自然科学基金(21171043): 抗肿瘤先导植物药、金属基药物与人血清白蛋白相互作用研究（80万元） (2012-2015)

（5）教育部创新团队（学术带头人，排名第二）：天然活性物质的发现、结构改造与功能（450万元，2013-2016）（300万元，2017-2019滚动）

（6）广西院士后备人选培养工程项目：中药活性成分无机药物及其载运体系研究（1500万元） (2017-2022)

（7）广西重点研发计划项目：小龙虾细菌性疾病防治的广西中草药开发与关键技术研究（182万元）（2021-2023）

（8）广西自然科学基金项目（重点项目）：基于中药活性成分异喹啉类生物碱金属抗肿瘤配合物研究（100万元）（2013-2015）

（9）企业委托技术开发课题：珠海派锐尔新材料有限公司：对萘二甲酸的合成技术开发（250万元）（2023-2024）

主要荣誉称号 

国家“万人计划”（百千万工程）领军人才（2016年）

广西院士后备人选培养工程首批人选（2016年）

中国科协“西部开发突出贡献奖”（2008年）

全国优秀科技工作者（2005年）

教育部第三届“高校青年教师奖”（2002年）

中国青年科技奖（2001年）

国家有突出贡献的中青年专家（1999年）

广西优秀专业技术人员（1999年）

“广西十百千人才工程”第一层次人选（1998年）

国家“百千万人才工程”首批人选（1996年）

国务院政府特殊津贴（1996年）